LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Pancreatic Pseudocyst after Fully Covered Self-expandable Metallic Stent Placement: A Case Report.

    Koizumi, Mitsuhito / Ishikawa, Sho / Marui, Kaori / Kokubu, Masahito / Okujima, Yusuke / Numata, Yuki / Imamura, Yoshiki / Kumagi, Teru / Hiasa, Yoichi

    Internal medicine (Tokyo, Japan)

    2024  

    Abstract: A 70-year-old woman presented with stage III pancreatic head cancer. After endoscopic sphincterotomy, a fully covered self-expandable metallic stent (FCSEMS) was placed in the common bile duct to manage jaundice. The patient developed a fever and ... ...

    Abstract A 70-year-old woman presented with stage III pancreatic head cancer. After endoscopic sphincterotomy, a fully covered self-expandable metallic stent (FCSEMS) was placed in the common bile duct to manage jaundice. The patient developed a fever and abdominal pain 40 days after stent placement, with a suspected diagnosis of infected pancreatic pseudocyst. Purulent discharge from the papilla was observed during FCSEMS removal, and pancreatography revealed a pseudocyst connected to the main pancreatic duct. The pancreatic pseudocyst resolved after transpapillary drainage. Pancreatic pseudocysts should be suspected after biliary FCSEMS placement, and prompt removal and endoscopic drainage of the FCSEMS should be considered.
    Language English
    Publishing date 2024-02-26
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.3178-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.

    Hino, Kaori / Nishina, Tomohiro / Numata, Yuuki / Asagi, Akinori / Inoue, Tomonori / Yoshimatsu, Megumi / Sakaguchi, Chihiro / Nakasya, Akio / Nishide, Norifumi / Kajiwara, Takeshi / Terao, Takashi / Nadano, Seijin / Marui, Kaori / Okujima, Yusuke / Kokubu, Masahito / Imamura, Yoshiki / Kanemitsu, Kozue / Koizumi, Mitsuhito / Kumagi, Teru /
    Hiasa, Yoichi / Hyodo, Ichinosuke

    Internal medicine (Tokyo, Japan)

    2022  Volume 61, Issue 15, Page(s) 2255–2261

    Abstract: Objective S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouracil/leucovorin ... ...

    Abstract Objective S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy was approved as an alternative in Japan in 2020. However, the clinical outcomes of S-1 and mFFX after GnP have scarcely been reported. Therefore, we retrospectively studied them. Methods We extracted the clinical data of 86 patients with UPC who received second-line chemotherapy after GnP between 2015 and 2020. Among the patients who had a good organ functions and no massive ascites, 41 patients treated with S-1 and 21 treated with mFFX were enrolled. Results Compared to S-1, mFFX tended to be used for younger patients with a good general condition (median age, 63 vs. 71 years, p<0.01; and performance status 0, 67% vs. 37%, p<0.05). The median progression-free and overall survival were similar between the S-1 (3.7 and 7.2 months, respectively) and mFFX (3.3 and 7.4 months, respectively) groups. The response rate in patients with measurable lesions was 4% (n=1/23) in the S-1 group and 17% (n=2/12) in the mFFX group. The incidence of grade 3 or 4 adverse events was 20% in the S-1 group and 57% (neutrophil count decreased in 43%) in the mFFX group (p<0.01). Conclusion S-1 and mFFX were both acceptable second-line chemotherapies after GnP therapy for UPC, although attention should be paid to myelosuppression during mFFX treatment. Further studies involving nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy are necessary to facilitate the selection of the optimal regimen for each patient.
    MeSH term(s) Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/analogs & derivatives ; Fluorouracil ; Humans ; Irinotecan/adverse effects ; Leucovorin/adverse effects ; Middle Aged ; Oxaliplatin ; Paclitaxel/therapeutic use ; Pancreatic Neoplasms/pathology ; Retrospective Studies ; Gemcitabine ; Pancreatic Neoplasms
    Chemical Substances 130-nm albumin-bound paclitaxel ; Albumins ; folfirinox ; Oxaliplatin (04ZR38536J) ; Deoxycytidine (0W860991D6) ; Irinotecan (7673326042) ; Paclitaxel (P88XT4IS4D) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT) ; Gemcitabine
    Language English
    Publishing date 2022-08-01
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.8736-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease.

    Hiraoka, Atsushi / Onishi, Miho / Koyama, Satsuki / Kato, Masaya / Marui, Kaori / Murakami, Taisei / Onishi, Kei / Adachi, Tomoko / Matsuoka, Junko / Ueki, Hidetaro / Yoshino, Takeaki / Tsuruta, Miho / Aibiki, Toshihiko / Okudaira, Tomonari / Kuroda, Taira / Iwasaki, Ryuichiro / Suga, Yoshifumi / Miyata, Hideki / Ninomiya, Tomoyuki /
    Hirooka, Masashi / Abe, Masanori / Matsuura, Bunzo / Michitaka, Kojiro / Hiasa, Yoichi

    Internal medicine (Tokyo, Japan)

    2021  Volume 60, Issue 20, Page(s) 3195–3203

    Abstract: Objective This study evaluated cases of pruritus, which is known to be associated with sleep disorder, in chronic liver disease (CLD) patients. Methods Questionnaires were given to 339 enrolled CLD outpatients in winter (November 2019 to March 2020) and ... ...

    Abstract Objective This study evaluated cases of pruritus, which is known to be associated with sleep disorder, in chronic liver disease (CLD) patients. Methods Questionnaires were given to 339 enrolled CLD outpatients in winter (November 2019 to March 2020) and again in summer (April to October 2020) (median interval: 104 days). Relative changes in symptoms shown by a visual analogue scale (VAS) and Kawashima's pruritus score between winter and summer were evaluated in Study 1 (n=199), while Study 2 examined the clinical features of patients with sleep disorder based on the results of the second questionnaire (n=235, median age 70 years old; 141 men, liver cirrhosis 37%). Results Study 1. There was a significant relationship in VAS between daytime and nighttime for each season, as well as between winter and summer for each time period (p<0.001). A comparison of Kawashima's pruritus scores for the daytime and nighttime showed no significant seasonal differences (p=0.436 and 0.828, respectively). When Kawashima's score increased, so did the average VAS for both daytime (0:1:2:3:4=0.4±0.2:1.4±0.9:3.0±1.8:5.9±2.1:6.2±2.3) and nighttime (0:1:2:3:4=0.3±0.1:1.4±1.5:3.5±2.3:6.7±2.6:6.9±1.8) (p<0.001 for both). Study 2. Twenty subjects (8.5%) complained of sleep disorder. An elevated FIB-4 index (≥3.07) showed a good predictive value for sleep disorder (p<0.01). The cut-off for the daytime and nighttime VAS values for existing sleep disorder were 1.6 [area under the curve (AUC) 0.901] and 3.4 (AUC 0.931). The respective sensitivity, specificity, and positive and negative predictive values for sleep disorder based on Kawashima's score (≥2) were 0.85, 0.28, 0.10, and 0.95 for the daytime and 1.00, 0.29, 0.12, and 1.00 for the nighttime. Conclusion Intervention against pruritus is recommended in CLD patients with a high Kawashima's score (≥2) in any season, especially with an elevated FIB-4 index.
    MeSH term(s) Aged ; Humans ; Liver Diseases/complications ; Liver Diseases/epidemiology ; Male ; Pain Measurement ; Pruritus/diagnosis ; Pruritus/epidemiology ; Pruritus/etiology ; Sleep Wake Disorders/diagnosis ; Sleep Wake Disorders/epidemiology ; Sleep Wake Disorders/etiology ; Surveys and Questionnaires
    Language English
    Publishing date 2021-10-15
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.7129-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.

    Hiraoka, Atsushi / Kato, Masaya / Marui, Kaori / Murakami, Taisei / Onishi, Kei / Adachi, Tomoko / Matsuoka, Junko / Ueki, Hidetaro / Yoshino, Takeaki / Tsuruta, Miho / Aibiki, Toshihiko / Okudaira, Tomonari / Kuroda, Taira / Iwasaki, Ryuichiro / Suga, Yoshifumi / Miyata, Hideki / Ninomiya, Tomoyuki / Hirooka, Masashi / Abe, Masanori /
    Matsuura, Bunzo / Michitaka, Kojiro / Hiasa, Yoichi

    Cancer medicine

    2021  Volume 10, Issue 11, Page(s) 3584–3592

    Abstract: Background/aim: Low branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is known as an indicator of amino acid imbalance. We elucidated usefulness of newly developed albumin-bilirubin (ALBI) score as alternative methods of BTR in patients with ... ...

    Abstract Background/aim: Low branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is known as an indicator of amino acid imbalance. We elucidated usefulness of newly developed albumin-bilirubin (ALBI) score as alternative methods of BTR in patients with naïve hepatocellular carcinoma (HCC) retrospectively.
    Materials/methods: In 842 patients with HCC and without BCAA supplementation (71 years, male 614, Child-Pugh A:B:C = 689:116:37), relationships among BTR and clinical features were evaluated. Of those, 438 patients, with Milan criteria HCC, treated curatively were divided into the high-BTR (>4.4) (n = 293) and low-BTR (≤4.4) (n = 145) groups. The prognostic value of BTR was evaluated using inverse probability weighting (IPW) with propensity score.
    Results: The low-BTR group showed worse prognosis than the other (3-, 5-, 10-year overall survival rates: 88.9% vs. 86.3%/70.5% vs. 78.1%/38.1% vs. 52.3%, respectively; p < 0.001). Multivariate Cox-hazard analysis adjusted for IPW showed elderly (≥65 years) HR 2.314, p = 0.001), female gender (HR 0.422, p < 0.001), ECOG PS ≥2 (HR 3.032, p = 0.002), low platelet count (HR 1.757, p = 0.010), and low BTR (≤4.4) (HR 1.852, p = 0.005) to be significant prognostic factors. Both serum albumin level (r = 0.370, p < 0.001) and ALBI score (r = -0.389, p < 0.001) showed a significant relationship with BTR. Child-Pugh class B, modified ALBI grade (mALBI) 2a, and mALBI 2b predictive values for BTR were 3.589, 4.509, and 4.155 (AUC range: 0.735-0.770), respectively, while the predictive value of ALBI score for low-BTR (≤4.4) was -2.588 (AUC 0.790).
    Conclusion: ALBI score -2.588 was a predictor for low-BTR (≤4.4), which was prognostic factors for early HCC patients, and at least patients with mALBI 2b might have an amino acid imbalance.
    MeSH term(s) Aged ; Amino Acids, Branched-Chain/blood ; Bilirubin/blood ; Biomarkers/blood ; Carcinoma, Hepatocellular/blood ; Carcinoma, Hepatocellular/mortality ; Chronic Disease ; Epidemiologic Methods ; Female ; Humans ; Liver Diseases/blood ; Liver Diseases/complications ; Liver Diseases/mortality ; Liver Neoplasms/blood ; Liver Neoplasms/mortality ; Male ; Nutritional Status ; Prognosis ; Protein-Energy Malnutrition/blood ; Protein-Energy Malnutrition/diagnosis ; Serum Albumin/analysis ; Tyrosine/blood
    Chemical Substances Amino Acids, Branched-Chain ; Biomarkers ; Serum Albumin ; Tyrosine (42HK56048U) ; Bilirubin (RFM9X3LJ49)
    Language English
    Publishing date 2021-05-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2659751-2
    ISSN 2045-7634 ; 2045-7634
    ISSN (online) 2045-7634
    ISSN 2045-7634
    DOI 10.1002/cam4.3908
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top